.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Citi
Medtronic
Express Scripts
Daiichi Sankyo
Accenture
Cantor Fitzgerald
QuintilesIMS
Johnson and Johnson

Generated: December 17, 2017

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 0019172

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes► Subscribe► SubscribeYYINDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-002Aug 20, 2014RXYesYes► Subscribe► SubscribeYYINDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeYYINDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeYYINDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-002Apr 30, 2015RXYesYes► Subscribe► SubscribeYYINDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
GlaxosmithklineTRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION209482-001Sep 18, 2017RXYesYes► Subscribe► SubscribeYY
Glaxosmithkline ConsFLONASE SENSIMIST ALLERGY RELIEFfluticasone furoateSPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeYY
Glaxosmithkline ConsFLONASE SENSIMIST ALLERGY RELIEFfluticasone furoateSPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeYINDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeYINDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist